This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research aimed at understanding the viral and host factors that contribute to the development of recurrent respiratory papillomatosis (RRP) in children. The $446,728 award, made on July 5, 2024, will fund a project conducted by Children's Hospital Medical Center in Cincinnati, Ohio that runs through June 30, 2029. The key products or services to be delivered under this grant...
This Project Grant award of $660,205 from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), aims to identify small compound inhibitors that can block human papillomavirus (HPV) genome replication. The key products and services to be delivered include: Screening a library of compounds to identify those that effectively inhibit the three stages of HPV DNA replication (establishment, maintenance, and amplification). This will...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate how the human papillomavirus (HPV) E7 oncoprotein disrupts epithelial cell differentiation and promotes persistent HPV infection in the basal layer of stratified squamous epithelia. The $533,707 award, spanning May 2025 to April 2030, will be administered by Tufts University School of...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), will fund research to improve understanding of the role of human papillomavirus (HPV) integration structures in oropharyngeal squamous cell carcinoma (OPSCC) molecular heterogeneity. The $2,942,347 award, effective August 1, 2024 through April 30, 2029, will support the development of a novel targeted capture...
This federal Project Grant award of $544,768.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research aimed at understanding the mechanisms of papillomavirus tumor regression through inhibition of the MEK signaling pathway. The primary awardee, the University of New Mexico Health Sciences Center, will leverage single-cell and spatial transcriptomics, along with functional assays, to investigate how MEK inhibition alters intrinsic keratinocyte antiviral...
This federal Project Grant award of $630,506 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) aims to develop a highly effective therapeutic vaccine against cervical cancer associated with human papillomavirus (HPV) type 16 variants. The primary goals are to: 1) characterize immune evasion mechanisms of different HPV-16 E6/E7 variant epitopes; 2) evaluate growth and tumor microenvironment of spontaneous cervicovaginal carcinomas driven by prototype HPV-16 E6/E7 or...
This federal Project Grant award of $233,411 from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, will fund a randomized controlled trial (RCT) to evaluate the impact of a narrative communication intervention delivered through digital and mobile technology on human papillomavirus (HPV) vaccine initiation rates among children aged 9-12 years. The intervention involves producing videos featuring local cancer survivors sharing their...
This $642,488 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to determine the role of the MARCHF8 protein in promoting immune evasion of head and neck squamous cell carcinoma (HNSCC) driven by human papillomavirus (HPV). The key objectives are to: 1) Evaluate if targeting MARCHF8 can activate antitumor immunity by remodeling the tumor microenvironment in HPV+...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $184,528 to Case Western Reserve University to conduct research on the role of the vaginal microbiome and antibody-bound bacteria in human papillomavirus (HPV) infection and cervical dysplasia. The key objectives are to characterize the abundance, species/genera, and functional profiles of antibody-bound and unbound vaginal bacteria in women with and...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $515,812 to The Johns Hopkins University to study the progression of HPV-related oropharynx cancer (HPV-OPC) and how it differs between individuals with and without HIV. The study aims to: 1) characterize the impact of HIV on oral HPV16 persistence, 2) evaluate the performance of oral and blood biomarkers for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $148,280 to Childrens Hospital Medical Center in Cincinnati, Ohio to study the role of the ERBB2 protein in human papillomavirus (HPV)-induced pathologies.
The research aims to spatially resolve ERBB2 expression, activation, and downstream signaling in 3D organotypic epithelial raft models of HPV-positive and HPV-negative cells. The study will also define whether ERBB2 is required for the formation of a novel HPV-enriched cell population, viral genome copy number and expression, and HPV-driven pathologies, using genetic inhibition of ERBB2 and FDA-approved drugs. The results are expected to determine if ERBB2 signaling promotes the HPV viral life cycle and associated pathologies, and whether existing FDA-approved drugs can suppress clinically relevant HPV phenotypes to potentially prevent HPV-related cancers.